NCT03596593

Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors

Identifying Microsatellite Instability Status From Circulating Tumor DNA in Chinese Patients With Refractory Advanced Solid Tumors: a Large Molecular Epidemiological Investigation

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 8,000 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a molecular epidemiological investigation aiming to identify microsatellite instability status from circulating tumor DNA in Chinese patients with refractory advanced solid tumors.

Detailed description

This study is conducted in Chinese patients with advanced refractory metastatic solid tumors. A total of 8-10 mL of blood will be collected from eligible patients and used for extracting circulating tumor DNA. Blood-MSI status will be tested based on SPANOM technique developed by 3D Medicines Inc. Shanghai, China. Patients are encouraged to provide tissues collected from progressive disease for tissue-MSI testing (not required for inclusion).

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	SPANOM (identifying MSI status from ctDNA)	SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.

Timeline

• Start date: 2018-07-11
• Primary completion: 2020-06-01
• Completion: 2020-06-01
• First posted: 2018-07-24
• Last updated: 2018-07-24

Locations

1 site across 1 country: China